This growth is driven by gene therapies, antisense oligonucleotides (ASOs), and targeted biologics for conditions like SMA, DMD, ALS, and myasthenia gravis. https://finance.yahoo.com/news/neuromuscular-disease-therapeutics-market-reach-152000966.html